Article
A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Apr 2025
Goyal L, DiToro D, Facchinetti F, Martin E E, Peng P, Baiev I, Iyer R, Maurer J, Reyes S, Zhang K, Majeed U, Berchuck J E, Chen C T, Walmsley C, Pinto C, Vasseur D, Gordan J D, Mody K, Borad M, Karasic T, Damjanov N, Danysh B P, Wehrenberg-Klee E, Kambadakone A R, Saha S K, Hoffman I D, Nelson K J, Iyer S, Qiang X, Sun C, Wang H, Li L, Javle M, Lin B, Harris W, Zhu A X, Cleary J M, Flaherty K T, Harris T, Shroff R T, Leshchiner I, Parida L, Kelley R K, Fan J, Stone J R, Uboha N V, Hirai H, Sootome H, Wu F, Bensen D C, Hollebecque A, Friboulet L, Lennerz J K, Getz G, Juric D
Abstract excerpt
BACKGROUND: Fibroblast growth factor receptor (FGFR) inhibitors have significantly improved outcomes for patients with FGFR-altered cholangiocarcinoma, leading to their regulatory approval in multiple countries. As with many targeted therapies, however, acquired resistance limits their efficacy. A comprehensive, multimodal approach is crucial to characterizing resistance patterns to FGFR inhibitors. PATIENTS AND...
Topics
Join the communities discussing this publication.